NDA 018074 · Acertis Pharms
Phendimetrazine Tartrate
Phendimetrazine Tartrate · Oral
Last checked: Nov 20, 2026Latest source record: Nov 13, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1979
Apr 16, 1979
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
0 Phase 3, 0 recruiting
FAERS reports
58
23 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 19, 2025.
INDICATIONS AND USAGE Phendimetrazine tartrate extended-release capsules are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of greater than or equal to 30 kg/m 2 or greater than or equal to 27 kg/m 2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters The usefulness of agents of this class (see CLINICAL PHARMACOLOGY ) should be measured against possible risk factors inherent in their use such as those described below. Phendimetrazine tartrate is indicated for use as monotherapy only. Body Mass Index Table
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 16, 1979 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- PHENDIMETRAZINE TARTRATE · PHENDIMETRAZINE TARTRATE 105MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Phendimetrazine" as an intervention, any sponsor and status, largest first.
William StoopsAcademic, hospital or other
NCT02522325 · 30 participants · Start Aug 2015 · Primary completion Dec 2018
Drug: Phendimetrazine; Cocaine and 1 more · For: Cocaine Use Disorder
Sites: Lexington, Kentucky
- Phendimetrazine and CocaineCompleted
William StoopsAcademic, hospital or other
NCT02233647 · 11 participants · Start Sep 2014 · Primary completion Dec 2015
Drug: Cocaine; Placebo · For: Cocaine Use Disorder
Sites: Lexington, Kentucky
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective9
- pain7
- headache6
- weight increased6
- back pain5
- wrong technique in product usage process5
- choroidal effusion4
- dyspnoea4
- fatigue4
- myopia4
- ocular hypertension4
- off label use4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 3 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 7 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 8 |
| 2025 | 3 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Abuse Potential of Oral Phendimetrazine in Cocaine-dependent Individuals: Implications for Agonist-like Replacement Therapy.
Bolin BL, Stoops WW, Sites JP, et al. · J Addict Med 2016 · Controlled Clinical Trial, Research Support, N.I.H., Extramural
- Influence of phendimetrazine maintenance on the reinforcing, subjective, performance, and physiological effects of intranasal cocaine.
Stoops WW, Strickland JC, Alcorn JL, et al. · Psychopharmacology (Berl) 2019 · Randomized Controlled Trial
- Availability of phendimetrazine from sustained and non-sustained action formulations.
Müller FO, Hundt HK, Gosling JA · S Afr Med J 1975 · Clinical Trial, Controlled Clinical Trial
- [The acute effect of a long-acting anorexigenic substance, phendimetrazine pamoate, on the mobilization of plasma lipids in man].
Charbonnier A, Nepveux P, Neuman M, et al. · Therapie 1976 · Clinical Trial, Comparative Study
- Sustained-action phendimetrazine in obesity.
Hadler AJ · J Clin Pharmacol J New Drugs 1968 · Clinical Trial, Controlled Clinical Trial
Sponsor: Acertis Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.